Role of brachytherapy in the treatment of localized prostate cancer
Abstract
The review is devoted to application of brachytherapy for treating the localized prostate cancer (PC). Statistics for incidence and detectability of this pathology and its dynamics for recent years are represented. Brief analysis of other methods which are conveniently used for treatment of PC, such as radical prostatectomy and external-beam radiotherapy, was performed. Advantages and disadvantages of these methods have been discussed. Brief history about the development of brachytherapy from first experience to wide-spread use in clinical practice is reported. The detailed review of series of large trials from Russia and other countries for efficiency and safety of brachytherapy in patients with prostate cancer for recent 15 years is also represented. Two types of brachytherapy in current clinical oncology i.e. low-dose technique with permanent implantation of microsources and high-dose temporary isotope implantation, specifics of its application in different groups of patients have been described. The procedure of brachytherapy and its three main steps i.e. planning, implantation and control assessment after implantation have been characterized in details. The conclusion about benefits of using of brachytherapy in the treatment of prostate cancer as minimally invasive and efficient method was made.
About the Authors
A. D. Kaprin
P.A. Herzen MCRI (branch of FSBI «NMRRC» of the Ministry of Health of the Russian Federation), Moscow, Russia
Russian Federation
Russian Federation
V. N. Galkin
P.A. Herzen MCRI (branch of FSBI «NMRRC» of the Ministry of Health of the Russian Federation), Moscow, Russia
Russian Federation
Russian Federation
S. A. Ivanov
P.A. Herzen MCRI (branch of FSBI «NMRRC» of the Ministry of Health of the Russian Federation), Moscow, Russia
Russian Federation
Russian Federation
References
1. Zabolevaemost' naseleniya Rossii v 2003 godu. Statisticheskie materialy (Incidence in Russian population in 2003. Statistical data), M.: GEOTAR-MED, 2004, p. 1–68.
2. Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost' i smertnost') (Malignant neoplasms in Russia in 2013 (incidence and mortality), Pod red. A.D. Kaprina, V.V. Starinskogo, G.V. Petrovoi, M.: MNIOI im. P.A. Gertsena – filial FGBU «FMITs im. P.A. Gertsena» Minzdrava Rossii, 2015, p. 1–250.
3. DeAngelis R., Sant M., Coleman M.P. et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE- 5-a population-based study, Lancet Oncol, 2014, Vol. 15 (1), p. 23–34.
4. Godtman R.A., Holmberg E., Khatami A. et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial, Eur Urol, 2013, Vol. 63 (1), p. 101–107.
5. Klotz L. Active surveillance for prostate cancer: trials and tribulations, World J Urol, 2008, Vol. 26 (5), p. 437–442.
6. Nag S. A brief history of brachytherapy, Brachytherapy, 2009, Vol. 7 (1), p. 55–59.
7. Gupta V.K. Brachytherapy – past, present and future, Journal of Medical Physics, 1995, Vol. 20, p. 31–38.
8. Zelefsky M.J., Nedelka M.A., Arican Z.L. et al. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy, Brachytherapy, 2008, Vol. 7 (1), p. 1–6.
9. Sh D., Flynn A., Batterman J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer, Radiother Oncol, 2000, Vol. 57 (3), p. 315–321.
10. Grimm P.D., Blasko J.C., Sylvester J.E. et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125-I brachytherapy, Int J Radiat Biol Phys, 2001, Vol. 51 (1), p. 31–40.
11. Potters L., Klein E.A., Kattan M.W. et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation, Radiother Oncol, 2004, Vol. 71 (1), p. 29–33.
12. Sylvester J.E., Blasko J.C., Grimm R. et al. Fifteen year follow-up of the first cohort of localized prostate cancer patients treated with brachytherapy, J Clin Oncol, 2004, Vol. 22 (14), p. 45–67.
13. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 2005, Vol. 173 (5), p. 1562–1566.
14. Stone N.N., Stock R.G., Unger P. Intermediate term biochemical-free progression and local control following 125-iodine brachytherapy for prostate cancer, J Urol, 2005, Vol. 173 (3), p. 803–807.
15. Zelefsky M.J., Kuban D.A., Levy L.B. et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int J Radiat Oncol Biol Phys, 2007, Vol. 67 (2), p. 327–333.
16. Lawton C.A., DeSilvio M., Lee W.R. et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05), Int J Radiat Oncol Biol Phys, 2007, Vol. 67 (1), p. 39–47.
17. Peinemann F., Grouven U., Hemkens L.G. Low-dose rate brachytherapy for men with localized prostate cancer, Cochrane Database Syst Rev, 2011.
18. Grimm P., Sylvester J. Advances in Brachytherapy, Rev Urol, 2004, Vol. 6, Suppl. 4, p. 37–48.
19. Ferrer M., Suárez J.F., Guedea F. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer, Int J Radiat Oncol Biol Phys, 2008, Vol. 72 (2), p. 421–432.
20. Takam R., Bezak E., Yeoh E. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model, Phys Med Biol, 2009, Vol. 54 (3), p. 611–625.
21. Baxter N.N., Trepper J.E., Durham S.B. et al. Increased risk of rectal cancer after prostate radiation: a population-based study, Gastroenterology, 2005, Vol. 128 (4), p. 819–824.
22. Liauw S.L., Sylvester J.E., Morris C.G. et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up, Int J Radiat Oncol Biol Phys, 2006, Vol. 66 (3), p. 669–673.
23. Hinnen K.A., Schaapveld M., van Vulpen M. Prostate brachytherapy and second primary cancer risk: a competitive risk analysis, J Clin Oncol, 2011, Vol. 29 (34), p. 4510–4515.
24. Apolikhin O.I., Sivkov A.V., Oshchepkov V.N. i dr. 10-letnii opyt brakhiterapii raka predstatel'noi zhelezy: klinicheskie rezul'taty i ekonomicheskie otsenki (10-year experience on brachytherapy for prostate cancer: clinical results and economic assessments), Vestnik RNTsRR Minzdrava Rossii, 2011, T. 3, No. 11, p. 114–127.
25. Razreshenie na primenenie novoi meditsinskoi tekhnologii FS № 2009/218 ot 27.07.2009. Brakhiterapiya lokalizovannogo raka predstatel'noi zhelezy (Permission for use of new medical technology FS № 2009/218 dated 27.07.2009. Brachytherapy of localized prostate cancer), A.D. Kaprin, G.A. Pan'shin, I.A. Al'bitskii i soavt., p. 1–21.
Review
For citations:
Kaprin A.D., Galkin V.N., Ivanov S.A. Role of brachytherapy in the treatment of localized prostate cancer. Biomedical Photonics. 2015;4(4):21-26. (In Russ.)
Views:
1074
Email this article 